Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting
Lund, Sweden — 30 October 2017 — Camurus today announced that the US Food and Drug Administration (FDA) has published the briefing material for the joint Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting on 1 November 2017 to discuss the New Drug Application (NDA) for approval of CAM2038, an investigational buprenorphine weekly and monthly depot subcutaneous injection for the treatment of opioid use disorder. Advisory committees provide FDA with independent advice from outside experts. The FDA is not bound by the committee's
